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ABSTRACT
Background
Hematopoietic stem cells (HSCs) or repopulating cells are able to self-renew and differentiate
into cells of all hematopoietic lineages, and they can be enriched using the CD34 cell surface
marker. Because of this unique property, HSCs have been used for HSC transplantation and
gene therapy applications. However, the inability to expand HSCs has been a significant
limitation for clinical applications. Here we examine, in a clinically relevant nonhuman primate
model, the ability of HOXB4 to expand HSCs to potentially overcome this limitation.
Methods and Findings
Using a competitive repopulation assay, we directly compared in six animals engraftment of
HOXB4GFP (HOXB4 green fluorescent protein) and control (yellow fluorescent protein [YFP])–
transduced and expanded CD34
þ cells. In three animals, cells were infused after a 3-d
transduction culture, while in three other animals cells were infused after an additional 6–9 d of
ex vivo expansion. We demonstrate that HOXB4 overexpression resulted in superior
engraftment in all animals. The most dramatic effect of HOXB4 was observed early after
transplantation, resulting in an up to 56-fold higher engraftment compared to the control cells.
At 6 mo after transplantation, the proportion of marker gene–expressing cells in peripheral
blood was still up to 5-fold higher for HOXB4GFP compared to YFP-transduced cells.
Conclusions
These data demonstrate that HOXB4 overexpression in CD34
þ cells has a dramatic effect on
expansion and engraftment of short-term repopulating cells and a significant, but less
pronounced, effect on long-term repopulating cells. These data should have important
implications for the expansion and transplantation of HSCs, in particular for cord blood
transplantations where often only suboptimal numbers of HSCs are available.
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Hematopoietic stem cells (HSCs) have the unique property
of being able to self-renew and differentiate into cells of all
hematopoietic lineages. Expansion of HSCs has many
potential applications in clinical settings, including stem cell
transplantation and stem cell gene therapy. Cord blood
transplantation has been increasingly used for the treatment
of hematopoietic disorders because of its rapid accessibility
and a lower risk of graft-versus-host disease even in a human
leukocyte antigen mismatched setting [1]. However, the
limited number of cord blood cells available in one unit,
particularly for adult patients, has resulted in delayed
engraftment and an increased risk of infections after cord
blood transplantation [2,3]. Thus, cord blood expansion has
been proposed to improve engraftment [4]. Expansion of
HSCs may also improve current HSC gene therapy protocols,
e.g., an increased number of gene–modiﬁed/corrected cells
may improve engraftment after nonmyeloablative condition-
ing [5]. Ex vivo expansion may also allow for improved safety
screening for gene-modiﬁed clones harboring unfavorable
integration sites.
The different approaches to stem cell expansion can be
divided into three categories. First, the use of cytokines, such
as Flt-3 ligand (Flt3-L), stem cell factor (SCF), and thrombo-
poietin (TPO) [6–11]; second, the use of stroma, such as bone
marrow stromal cells and endothelial cells, to support long-
term culture [12–16]; and third, the use of the stem cell self-
renewal genes, such as HOXB4 and genes in the Notch and
WNT signaling pathways. Constitutively active Notch1 has
been shown to immortalize murine HSCs and to favor
lymphoid lineage differentiation rather than myeloid lineage
differentiation [17]. Growth-enhancing effects of Notch4 on
human cord blood HSCs have also recently been reported
[18]. Expression of modiﬁed b-catenin or treatment of cells
with WNT3a protein can expand mouse HSCs more than 100-
fold without leukemogenesis [19,20]. However, no marked
effect on human HSCs was observed. Overexpression of the
human HOXB4 gene has been shown to induce ex vivo
expansion and self-renewal of murine long-term multi-
lineage repopulating HSCs without compromising differ-
entiation or homeostatic regulation of the HSC pool size [21].
More recently, a TAT-HOXB4 fusion protein has been
developed as a reagent that is able to stimulate expansion
of mouse HSCs [22] when added to liquid cultures.
Furthermore, in vivo and ex vivo expansion of human cord
blood CD34
þ cells by HOXB4 overexpression or by direct
delivery of HOXB4 was observed, although not to the same
extent as observed in mouse cells [23–25].
Experimental preclinical studies to determine the effect of
HOXB4 overexpression on human hematopoietic repopulat-
ing cells can be performed only in an xenogeneic trans-
plantation model such as the NOD/SCID (nonobese diabetic/
severe combined immunodeﬁcient) mouse model, which is
generally limited by the relatively short life span of the
recipients and the inability to support differentiation into all
hematopoietic lineages. Thus, in the current study we wished
to examine the effect of HOXB4 overexpression in a clinically
relevant large-animal transplantation model. We chose the
nonhuman primate model because it is a well-established
preclinical model for HSC gene transfer, expansion, and
transplantation. Using a competitive repopulation assay, we
studied the effect of HOXB4 on hematopoietic repopulation
with cells that were infused directly after a 3-d transduction
period or after an additional 6–9 d of ex vivo expansion.
Methods
Animals
Pig-tailed macaques (Macaca nemestrina) were housed in the
primate center at the University of Washington. Animals
were handled in accordance with the guidelines set by the
American Association for Accreditation of Laboratory
Animal Care, and the protocols were approved by the Animal
Care and Use Committee of the Fred Hutchinson Cancer
Research Center and the University of Washington.
Macaques were treated with recombinant human (rhu) G-
CSF (Amgen, Thousand Oaks, California, United States), 100
lg/kg daily given as subcutaneous injections for 5 d. On day 5,
either bone marrow was harvested from the humeri and/or
femora, or mobilized peripheral blood cells were collected by
leukapheresis. In preparation for transplantation, all animals
received myeloablative total-body irradiation. 24 h after
transplantation, the animals were started on G-CSF at 100 lg/
kg daily, given as intravenous injection, until the animals
started to engraft. Standard supportive care, including blood-
product transfusions, ﬂuid and electrolyte management, and
antibiotics, was administered as needed. Hematopoietic recov-
ery was monitored by daily complete blood counts. Animals
R01019 and T02266 were euthanized by the veterinary staff
owing to poor condition. Animal R01019 was euthanized on
day17.Theanimalhadnotrecoveredwellfromtheirradiation,
became hypothermic, and developed ischemic kidney damage.
T02266 was euthanized on day 47. Necropsy ﬁndings revealed
histopathologicalchangesconsistentwithradiationdamage. In
addition, the animal appeared to have a papovavirus-induced
nephritis. Findings in both animals were consistent with
transplantation/irradiation–associated toxicity.
Retrovirus Preparation
Derivation of the gammaretroviral vector plasmid MSCV-
HOXB4-ires-GFP (green ﬂuorescent protein) from the origi-
nal MSCV backbone provided by R. Hawley [26] has been
described previously [21]. The control, MSCV-ires-YFP (yellow
ﬂuorescent protein) was generated by inserting the coding
regionoftheeYFPreportergeneinplaceoftheeGFPreporter
gene of the previously described MSCV-ires-GFP vector [21].
The vectors were used to transiently transfect 293T-based
Phoenix-RD114 packaging cells. The resulting virus-contain-
ing media were used to transduce Phoenix-gibbon ape
leukemia virus (GALV) packaging cells as described earlier
[27]. A helper virus-free high-titer clone was selected. Virus-
containing medium was collected in DMEM supplemented
with 10% fetal bovine serum (FBS) and 1% penicillin/
streptomycin from monolayers of Phoenix-GALV producer
cells after incubation for 12 h at 37 8C. This cell line produced
virus at a titer of 1310
5 to 2310
5 CFU/ml when assayed with
HT1080 cells. Fresh vector supernatant was passed through a
0.22-lm ﬁlter (Millipore, Bedford, Massachusetts, United
States) and preserved at 80 8C for later transduction.
Transduction of CD34
þ Cells
CD34 cell enrichment was performed using the 12.8 IgM
anti-CD34 antibody and MACS IgM microbeads (Miltenyi
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Expansion of Primate Repopulating CellsBiotec, Auburn, California, United States) according to the
manufacturer’s instructions and as described previously
[28,29]. The average purity of CD34
þ cells in the enriched
product was 64% (range, 45%–79%) as determined by ﬂow
cytometry. CD34
þ cells were split into two equal fractions;
one fraction was transduced with the HOXB4 green
ﬂuorescent protein (HOXB4GFP) vector and the other
fraction with the YFP control vector. The use of two different
markers, GFP versus YFP, for the two different culture
conditions allows for the use of a competitive repopulation
approach, i.e., following transduction/expansion, cells from
both fractions are pooled and infused into the recipient after
myeloablative irradiation. Cells from the two different
culture conditions can then be easily detected in vivo by
analyzing peripheral blood cells for the presence of GFP
þand
YFP
þ cells. CD34-enriched macaque cells were cultured in
Iscove’s modiﬁed Dulbecco’s medium (IMDM)/10% FBS
supplemented with 100 ng/ml rhuSCF, 100 ng/ml rhuFlt3-L,
100 ng/ml interleukin (IL)-3, 100 ng/ml IL-6, 100 ng/ml
Thrombopoietin (TPO), and 100 ng/ml G-CSF for 2 d before
transduction. For transduction, 2.5 3 10
5 cells/ml were
cultured with ﬁltered vector supernatant at a multiplicity of
infection of 0.3, supplemented with the same cytokine
combination in ﬂasks previously coated with the CH-296
fragment of ﬁbronectin (Retronectin, Takara, Shiga, Japan)
for 4 h. 24 h later, nonadherent cells were collected, spun
down, and resuspended in fresh vector supernatant and
cytokines and added back to the same ﬁbronectin-coated
ﬂask. 4 h later, cells were harvested for transplantation,
colony-forming cell (CFC) assay, or long-term liquid culture.
Long-Term Ex Vivo Culture
HOXB4GFP- or YFP-transduced cells were maintained in
the same culture media as used for transduction in tissue-
culture-treated 24-well plates (Nunc, Rochester, New York,
United States). Cultures were split every week at a ratio of 1:2
to 1:10 and the cell density adjusted to 2–5310
5/ml with fresh
media and cytokines. Once a week, some cells were harvested
for ﬂow analysis to determine the percentages of
HOXB4GFP
þ or YFP
þ cells and for CFC assays.
Ex Vivo Expansion of Macaque CD34
þ Cells for
Transplantation
G-CSF–primed macaque bone marrow cells were puriﬁed
as described previously. CD34
þ cells were cultured in IMDM/
10% FBS with addition of SCF, TPO, Flt3-L, and G-CSF, each
at 100 ng/ml. After transduction with HOXB4GFP- or YFP-
containing viral vectors, cells were cultured in CH296-coated
ﬂasks with the same culture medium and cytokines. After a
further 6–9 d of culture, all the cells were harvested for
transplantation.
CFC Assays
CFC assays were performed in two-layer agarose in MEM
with 20% FBS supplemented with 4 U/ml rhu erythropoietin
(Amgen), and SCF, GM-CSF, G-CSF, IL-6, and IL-3 each at 100
ng/ml at 37 8C. Between days 12 and 14, colonies of more than
50 cells were counted.
Taqman PCR Analysis
HOXB4GFP-Genomic DNA was extracted using the
QIAamp DNA blood kit (Qiagen, Valencia, California, United
States). The primers and conditions used for GFP/YFP and b-
actin PCR have been described previously [30].
For every PCR analysis, negative controls included DNA
from normal peripheral blood samples extracted with the
same methodology and a reagent control. Serial dilutions of
DNA (containing a single copy of an integrated vector per cell)
into normal macaque peripheral blood DNA were used as
positive controls for generating the control regression curve.
Flow Cytometry
Flow-cytometric analysis was performed for GFP/YFP
expression using a Vantage instrument and CellQuest
software (Becton Dickinson, San Jose, California, United
States). More than 20,000 events were analyzed for each
Figure 1. Efficient HOXB4-Mediated Ex Vivo Expansion of M. nemestrina
CD34
þ Cells
The mean and standard deviation of four independent experiments are
shown. HOXB4GFP- or YFP (control)–transduced M. nemestrina bone
marrow CD34
þ cells were kept in liquid culture for 4 wk. Culture media
were changed regularly to keep cells at optimum densities.
(A) Percentage of HOXB4GFP
þ or YFP
þ cells.
(B) Fold expansion of total nucleated cells.
(C) Fold expansion of CFCs.
DOI: 10.1371/journal.pmed.0030173.g001
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Expansion of Primate Repopulating Cellssample. Non-transduced cells were used as a control for the
gating of positive cells. For subset analysis, anti-CD14-PE,
anti-CD3-APC-Cy7, anti-CD13-APC, and anti-CD20-PE were
used. All antibodies were purchased from Becton Dickinson.
Linear Amplification–Mediated Polymerase Chain
Reaction
Integration-site analysis by linear ampliﬁcation–mediated
polymerase chain reaction (LAM-PCR) was performed with
DNA isolated from FACS (ﬂuorescence-activated cell sorter)–
sorted HOXB4GFP
þ or YFP
þ peripheral blood cells. One
hundred nanograms of DNA was used as template for LAM-
PCR that was performed as described previously with
modiﬁcations [31,32]. Brieﬂy, TasI was used to digest DNA
after initially amplifying and creating double-stranded DNA.
An enzyme-speciﬁc linker cassette was ligated into the TasI-
restriction overhangs, and two additional rounds of PCR
ampliﬁed the virus long-terminal repeat and genomic
ﬂanking regions. PCR products were visualized on spreadex
gels (Elcrom Scientiﬁc, Cham, Switzerland).
Western Blot
White blood cells of bone marrow or peripheral blood
samples from animals were obtained by lysis buffer treat-
ment. HOXB4GFP
þ cells were sorted by FACS to a purity of
99%. Proteins were extracted by radio-immunoprecipitation
assay buffer with fresh addition of 1% protease-inhibitor
cocktail (Sigma, St. Louis, Missouri, United States). Proteins
were separated by SDS-polyacrylamide gel electrophoresis
and subsequently blotted onto PVDF membranes. HOXB4
was detected after incubation with supernatant from I12, a
hybridoma secreting rat anti-mouse HOXB4 antibody, which
cross-reacts with human HOXB4 (I12; Developmental Studies
Hybridoma Bank, University of Iowa, Iowa, United States).
Visualization of bound antibodies was performed with the
goat anti-rat horseradish peroxidase–conjugated secondary
antibody with subsequent enhanced chemiluminescence
reaction (ECL Kit, Amersham Biosciences, Little Chalfont,
United Kingdom). The membranes were stained with Blue-
stain (Pierce Biotechnology, Rockford, Illinois, United States)
as protein-loading controls.
Statistical Analysis
Student’s paired t-tests were used for the analysis of both in
vitro and in vivo comparisons. For the in vivo analyses, we
used days 1–50 to analyze early engraftment and days 51 and
onwards to analyze late engraftment. Within each time
period, the marking was averaged within each monkey.
Paired differences were then computed for each monkey or
culture experiment, either comparing HOXB4GFP and YPF
marking within the same time period, or comparing
HOXB4GFP marking between time periods. A log-trans-
formation was applied for the analysis of fold increase in total
cell expansion and CFC yield in culture before computing
paired differences.
Results
HOXB4-Mediated Expansion of M. nemestrina Progenitor
Cells
We ﬁrst investigated the effects of HOXB4 overexpression
on ex vivo expansion of CD34
þ cells from macaque bone
marrow. CD34
þ cells were transduced with an HOXB4-
expressing gammaretroviral vector MSCV-HOXB4-ires-GFP
or with a control vector MSCV-ires-YFP. After culture, the
percentage of HOXB4-overexpressing macaque cells (detected
by expression of the linked GFPreporter gene) increased from
32.4% (standard deviation 12.2%) on day 3 to 81.0% (standard
deviation 12.2%) on day 24, while the proportion of YFP
þ
(control)–transduced cells remained essentially unchanged,
from 38% (standard deviation 14.7%) on day 3 to 43.5%
(standard deviation 15.4%) on day 24. A signiﬁcant difference
was observed on day 24 (p¼0.007, paired t-test; n¼4). HOXB4
overexpression was also associated with a 3- to 5-fold increase
in total cell expansion (mean 1,720-fold, standard deviation
1,214-fold) on day 24 when compared with YFP-transduced
control cells (mean 671-fold, standard deviation 637-fold) on
day 24 (p ¼ 0.01, paired t-test) (Figure 1). An even more
pronounced effect of HOXB4 was observed on CFC progen-
itors. HOXB4 overexpression induced an up to 7-fold increase
in the expansion of CFCs (mean 147-fold, standard deviation
141-fold) compared to the YFP control (mean 21-fold,
standard deviation 18-fold) after 24 d in in vitro culture (p ¼
0.005, paired t-test). Taken together, HOXB4 overexpression
conferred a growth advantage to total nucleated cells and CFC
progenitors in long-term liquid culture.
Improved Engraftment of HOXB4GFP-Transduced
Repopulating Cells
We further investigated whether HOXB4 would allow for
expansion of repopulating HSCs. Mobilized CD34
þ periph-
eral blood cells were divided into two equal fractions for
Table 1. Summary of CD34 Enrichment, Infusion, Transduction Efficiency, and Follow-Up of the Animals Transplanted with HOXB4GFP-
or YFP-Transduced Cells
Animal
Number
Vector Number of
Selected
CD34
þ Cells
Fold Expansion
during
Transduction
Infused CFCs
after
Transduction
FACS on
Day 4 (%)
Follow-Up (wk) ANC , 100/ll (d) Status
R01019 HOXB4GFP 4 3 10
6/kg 5.5 7.3 3 10
4 45 2 10 Euthanized
a
YFP 4 3 10
6/kg 5.5 7.8 3 10
4 36
K00339 HOXB4GFP 3 3 10
6/kg 3 1.1 3 10
5 55 46 5 Alive
YFP 3 3 10
6/kg 3.2 1.1 3 10
5 40
M01035 HOXB4GFP 4 3 10
6/kg 2.1 2.9 3 10
5 36 56 7 Alive
YFP 4 3 10
6/kg 2.2 2.9 3 10
5 39
aEuthanized owing to transplant-related toxicity (see Methods).
DOI: 10.1371/journal.pmed.0030173.t001
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maretroviral vector. As shown in Table 1, the expansion, the
number of CFCs infused, and the transduction efﬁciency
were similar between HOXB4GFP- and YFP-transduced cells.
Immediately after the 3-day transduction period, all the cells
were transplanted into myeloablated animals (n ¼ 3).
In all three animals, R01019, K00339, and M01035, we
observed a similar engraftment pattern for HOXB4GFP- and
YFP-expressing cells (Figure 2). Although the engraftment
levels for HOXB4GFP
þand YFP
þcells were similar during the
ﬁrst 2 wk after transplantation, the percentage of
HOXB4GFP-expressing cells increased dramatically there-
after while the percentage of YFP-expressing cells decreased
in all animals. These engraftment kinetics led to a 2- to 9-fold
higher percentage of HOXB4GFP-expressing cells than YFP-
expressing cells between 2 and 7 wk after transplantation.
Across the time period, the engraftment of HOXB4GFP-
expressing cells (mean 36.9%, standard deviation 7.1%) was
more than double that of YFP-expressing cells (mean 15.8%,
standard deviation 6.1%) (p ¼ 0.08, paired t-test).
Marking levels eventually also declined for HOXB4GFP-
marked cells before they stabilized. In M01035, HOXB4GFP
marking stabilized at 15%–20% and YFP marking stabilized at
7%–10% at 6 mo post-transplantation, and marking levels
remained stable for more than 1 y (Figure 2). Marking levels in
K00339 stabilized at 1%–2% for HOXB4GFP and 0.5%–1%
for YFP. No immune responses were detected by lymphocyte-
proliferation assays to explain the decline in gene-marked
cells [33]. Gene-marking results as determined by Taqman
PCR showed higher levels than the ﬂow-cytometric data;
Figure 2. Improved Engraftment of HOXB4GFP-Transduced CD34
þ Cells
Equal numbers of macaque CD34
þcells were transduced in 3-d transduction cultures with either the HOXB4GFP- or YFP-expressing vector. Transduced
cells were infused into myeloablated animals. The percentage of HOXB4GFP
þ and YFP
þ granulocytes was assessed by flow cytometry. Shown is the
engraftment of HOXB4GFP
þ and YFP
þ granulocytes after transplantation.
DOI: 10.1371/journal.pmed.0030173.g002
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Expansion of Primate Repopulating Cellshowever,the overall pattern was similar tothe ﬂow-cytometric
results. Thus, the decline in GFP
þand YFP
þcells over time was
not due to gene silencing, and most likely reﬂected the
engraftment pattern of short-term repopulating cells.
Taken together, these results demonstrate a marked effect
of HOXB4 overexpression on engraftment of short-term
repopulating cells with a less pronounced effect on long-term
repopulating cells.
Improved Engraftment of HOXB4GFP-Transduced and
HOXB4GFP-Expanded Repopulating Cells
Based on the encouraging effect observed with
HOXB4GFP-transduced cells transplanted immediately after
transduction, we investigated whether more prolonged ex
vivo culture after transduction would lead to further
ampliﬁcation of the HOXB4 effect. To that end, cells were
cultured for an additional 6 d (K03290 and J02152) or 9 d
(T02266) after the transduction culture. Cells were cultured
in the presence of SCF, TPO, Flt3-L, and G-CSF. Table 2
shows the expansion and transduction efﬁciency of
HOXB4GFP- and YFP-expanded cells before infusion into
myeloablated animals.
CD34-enriched cells from the ﬁrst macaque (T02266) were
cultured for an additional 9 d after transduction. As shown in
Figure 3A, at 1 wk after transplantation, marking in
granulocytes was signiﬁcantly higher with the HOXB4GFP-
expanded cells (up to 85%) than with control YFP
þ cells. 2 wk
after transplantation, the difference was up to 35-fold,
suggesting HOXB4-mediated ex vivo expansion of cells that
contribute to early engraftment.
CD34-enriched cells from K03290 and J02152 were cultured
for an additional 6 d before transplantation. A similar pattern
in marking compared to T02266 was observed. In both K03290
and J02152, HOXB4GFP marking levels early after trans-
plantation were between 75% and 85%. In K03290, the
percentage of HOXB4-overexpressing cells was up to 14-fold
higher than the percentage of YFP-expressing cells on day 11
after transplantation. 5 mo after transplantation,
HOXB4GFP-marked granulocytes stabilized at 20% and YFP
þ
cells stabilized at around 4%, representing a 5-fold difference
(Figure 3B). In J02152, the maximum difference between
HOXB4GFP and YFP was 56-fold on day 16 (Figure 3C). As
shown in Table 2, in two out of the three animals that received
HOXB4-expanded cells, the absolute neutrophil count (ANC)
never dropped below 100/ll. Absolute numbers of gene-
marked cells are shown in Figure S1.
HOXB4-mediated ex vivo expansion resulted in signiﬁ-
cantly higher engraftment of granulocytes early (,50 d) after
transplantation (mean 38.1%, standard deviation 5.8%)
compared to engraftment after growth-factor-only expansion
(mean 5.7%, standard deviation 2.0%). (p ¼ 0.01, paired t-
test). As with the animals that received HOXB4GFP-trans-
duced CD34
þ cells without any additional ex vivo expansion,
the difference between HOXB4-mediated and growth-factor-
only expansion was less pronounced after day 50. In the four
animals that were assessed after day 50 (with and without ex
vivo expansion), the HOXB4-mediated engraftment (mean
11.5%, standard deviation 9.5%) was only marginally higher
than engraftment with YFP
þ cells (mean 3.8%, standard
deviation 3.8%) (p ¼ 0.09, paired t-test). However, in these
same four animals, the engraftment of HOXB4GFP
þ cells was
signiﬁcantly higher before day 50 (mean 40.7%, standard
deviation 4.0%) compared to engraftment after day 50 (mean
11.5%, standard deviation 9.5%) (p ¼ 0.02, paired t-test).
HOXB4-Mediated Expansion Results in Polyclonal
Repopulation
To determine whether HOXB4 overexpression expanded
multiple stem cell clones, we analyzed the clonal contribution
of HOXB4GFP- or YFP-transduced cells to repopulation in
K03290. As shown in Figure 4, integration-site analysis
revealed multiple clones for both HOXB4GFP- and YFP-
transduced cells. There was no obvious difference in the
number of unique bands derived from HOXB4-overexpress-
ing or YFP-expressing cells, suggesting that HOXB4-mediated
stem cell expansion in this setting allowed for polyclonal stem
cell expansion.
Effects of HOXB4 Overexpression on Hematopoietic
Subpopulations
At 3 and 6 mo post-transplantation, HOXB4GFP
þ or YFP
þ
cells were present in CD13
þ granulocytes, CD14
þ monocytes,
CD3
þ T cells, and CD20
þ B cells (Figures 5A and S2). Flow-
cytometric analysis showed that the percentage of
HOXB4GFP
þ cells was higher in CD13
þ and CD14
þ cells as
compared to YFP
þ cells, and in CD3
þ and CD20
þ cells this
ratio was reversed.
Differential silencing of HOXB4GFP in lymphocytes versus
granulocytes could have contributed to the differences in
Table 2. Summary of CD34 Enrichment, Ex Vivo Expansion of Total Cells and Infused CFCs, Transduction Efficiency, and Follow-Up of
the Animals Transplanted with Ex Vivo Expanded HOXB4GFP- or YFP-Expressing Cells
Animal
Number
Vector Number of
Selected
CD34
þ Cells
Fold Expansion
during Ex Vivo
Expansion
Infused CFCs
after
Expansion
FACS (%) Follow-Up (wk) ANC , 100/ll (d) Status
T02266 HOXB4GFP 2.2 3 10
6/kg 38 7.0 3 10
4 46 6 5 Euthanized
a
YFP 2.2 3 10
6/kg 36 3.3 3 10
4 49
K03290 HOXB4GFP 3.1 3 10
6/kg 38 1.85 3 10
5 39 26 0 Alive
YFP 3.1 3 10
6/kg 32 1.2 3 10
5 34
J02152 HOXB4GFP 4 3 10
6/kg 48 5.0 3 10
5 48 12 0 Alive
YFP 4 3 10
6/kg 49 1.7 3 10
5 74
aEuthanized owing to transplant-related toxicity (see Methods).
DOI: 10.1371/journal.pmed.0030173.t002
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þ cells in these subpopulations. To address this
issue, we used Taqman PCR to measure the copies of
HOXB4GFP or YFP integrants in FACS-sorted peripheral
blood cells. As shown in Figures 5B and S3, the higher
percentage of HOXB4GFP-expressing cells than YFP control
cells in the myeloid fraction was conﬁrmed. However, the
difference identiﬁed by Taqman PCR between HOXB4GFP
þ
cells and YFP
þ cells was less striking in the lymphoid fraction
comparedtotheﬂow-cytometricresults,suggestingsomegene
silencing or downregulation of HOXB4GFP in lymphocytes.
We also analyzed HOXB4GFP and YFP expression in red
blood cells and platelets. Figure 5C shows a representative
analysis of three animals at 3 mo after transplantation and
demonstrates that more red blood cells and platelets are
derived from HOXB4GFP
þ- than from YFP
þ-transduced cells.
These data suggest that HOXB4 has no negative effect on the
differentiation of megakaryocytes and erythrocytes.
Taken together, HOXB4 overexpression appears to have a
more pronounced effect on engraftment and differentiation
of myeloid than T-lymphoid precursors.
HOXB4 Protein Expression after Transplantation
We observed a differential effect of HOXB4 overexpression
on short- and long-term repopulating cells. To investigate a
putative mechanism, we examined HOXB4 expression in
HOXB4GFP-transduced cells from animals after transplanta-
tion. At 4 and 10 mo after transplantation, HOXB4GFP-
marked bone marrow cells were sorted by FACS to determine
Figure 3. Improved Engraftment of HOXB4GFP-Transduced and HOXB4GFP-Expanded CD34
þ Cells
Equal numbers of macaque CD34
þcells were transduced in 3-d transduction cultures with either the HOXB4GFP or YFP vector and then cultured for an
additional 9 d (T02266) or 6 d (K03290 and J02152) in the presence of SCF, TPO, Flt-3L, and G-CSF. All the transduced and expanded cells were infused
into myeloablated animals. The percentage of HOXB4GFP
þ and YFP
þ granulocytes was assessed by flow cytometry. Shown is the engraftment of
HOXB4GFP
þ and YFP
þ granulocytes after transplantation. (A) T02266, (B) K03290, and (C) J02152.
DOI: 10.1371/journal.pmed.0030173.g003
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Expansion of Primate Repopulating CellsHOXB4 expression. While HOXB4 could be detected at 4 mo
in bone marrow–derived CD34
þ cells, no HOXB4 was
detected at 10 mo after transplantation (Figure 6A).
We also compared HOXB4 expression in sorted
HOXB4GFP-overexpressing or YFP-expressing bone marrow
or peripheral blood cells. No detectable HOXB4 expression
was observed in YFP
þ bone marrow cells, conﬁrming the
speciﬁcity of the HOXB4 antibody. HOXB4 expression in
HOXB4GFP-sorted bone marrow and peripheral blood cells
was detected with a substantially higher level in the bone
marrow at 4 mo after transplantation (Figure 6B).
These results indicate differences in HOXB4 expression in
bone marrow earlier and later following transplantation and
also between bone marrow and peripheral blood. Thus, the
less-pronounced effect on long-term repopulating cells may
be due to downregulation of HOXB4 expression.
Discussion
This is, to our knowledge, the ﬁrst report evaluating
HOXB4-mediated HSC expansion in a clinically relevant
nonhuman primate model. We observed that HOXB4 over-
expression resulted in a dramatic increase in short-term
repopulating cells compared to control-transduced cells. The
effect was most pronounced when HOXB4GFP-transduced
cells were expanded for an additional 6 to 9 d after
transduction. Short-term engraftment was up to 56-fold
higher with HOXB4-overexpressing cells than with control-
transduced cells, potentially eliminating severe neutropenia.
Even though the percentage of HOXB4GFP
þ cells declined
over time, at 6 mo after transplantation the percentage of
HOXB4-overexpressing cells was still up to 5-fold higher than
the control, suggesting that HOXB4 overexpression has an
effect also on long-term repopulation.
In the three animals that received HOXB4GFP- or YFP-
transduced cells after a 3-d transduction culture without
further expansion, HOXB4GFP marking was lower than YFP
marking during the ﬁrst week after transplantation. This was
independent of the transduction efﬁciency of each vector. In
contrast, in the three animals transplanted with cells trans-
duced and expanded ex vivo for 6–9 d, HOXB4GFP marking
was higher than the YFP control at 1 wk after transplantation.
These ﬁndings suggest that the in vivo effect observed in these
animals was due to the expansion of short-term repopulating
cells, which was more pronounced after an additional 6–9 d of
expansionculture.Thisinterpretation isalsosupportedbythe
increased number of CFCs after the additional 6–9 d of
culture. We observed greater differences in both short-term
and long-term repopulating cells for the second group of
animals transplanted with cells transduced and expanded ex
vivofor6–9dcomparedwiththeﬁrstgroup;thismaybedueto
an ex vivo growth advantage or to selection of HOXB4-
overexpressing cells relative to the YFP control cells.
In the two animals (M01035 and K00339) that were
followed for 56 and 46 wk, respectively, HOXB4GFP marking
has remained 1- to 2-fold higher than YFP marking. For the
three animals (T02266, K03290, and J02152) that received ex
vivo-expanded cells, HOXB4GFP marking has remained
about 3- to 5-fold higher than YFP marking after 5 wk post-
transplantation. In the surviving animals (K03290 and
J02152), this difference was maintained for 26 wk. These data
suggest that HOXB4 overexpression may also lead to
expansion of long-term repopulating cells; however, under
the culture conditions so far examined, the effect was less
pronounced than the effect on early repopulating cells.
Integration-site analyses also conﬁrmed that HOXB4-medi-
ated stem cell expansion led to a polyclonal repopulation.
HOXB4 is the only gene known so far whose ectopic
expression confers a selective growth advantage and a
competitive repopulation advantage in vivo to murine HSCs,
without compromising differentiation or homeostatic regu-
lation of the HSC pool size [21]. No leukemogenesis has been
reported by the infusion of HOXB4-transduced repopulating
cells in mice. We also did not observe any leukemias or clonal
abnormalities in our monkeys. We are closely monitoring by
LAM-PCR the surviving animals for any development of
monoclonality or leukemia. These data should provide us
with unique information in a large-animal model with regard
to the leukemogenic potential of HOXB4 and its potential
effect on genes within close range of the HOXB4 insertion.
The lack of any development of leukemia or monoclonality
thus far may be in part explained by our ﬁnding that HOXB4
expression levels in vivo were lower than those in ex vivo
culture, and that no HOXB4 expression could be detected in
mature cells in peripheral blood. In addition, expression in
bone marrow cells decreased over time after transplantation.
These data suggest downregulation of HOXB4 expression
after transplantation. The decrease in HOXB4 expression
after transplantation may also be due to differential
expression in progenitors and long-term repopulating cells.
HOXB4 promotes stem cell self-renewal, which may result
in inhibition of differentiation or a delay in differentiation.
HOXB4 expression-level-dependent inhibition of lympho-
Figure 4. HOXB4-Mediated Expansion Results in Polyclonal Repopulation
LAM-PCR was performed on lysates of sorted peripheral blood cells from
K03290 at 3 mo post-transplantation. The lane on the far left is a 25-bp
DNA ladder. HOXB4GFP indicates a triplicate LAM-PCR analysis for DNA
from HOXB4GFP
þ cells. YFP indicates a triplicate LAM-PCR analysis for
DNA from YFP
þ cells.
DOI: 10.1371/journal.pmed.0030173.g004
PLoS Medicine | www.plosmedicine.org May 2006 | Volume 3 | Issue 5 | e173 0694
Expansion of Primate Repopulating Cellsmyeloid differentiation of human cord blood cells has been
reported in the NOD/SCID mouse model [24]. We observed
HOXB4GFP-marked cells in all hematopoietic subpopula-
tions, but the difference between HOXB4GFP and YFP was
greatest in granulocytes. In CD3
þ T lymphocytes, the
percentage of YFP
þ cells was higher than the percentage of
HOXB4GFP
þ cells. These ﬁndings suggest preferential ex-
pansion of myeloid cells. The difference between myeloid and
Figure 5. Differential Effects of HOXB4 Overexpression on Granulocyte and Lymphocyte Engraftment and Marking Levels in Platelets and Red Blood
Cells
(A) Flow-cytometric analysis of CD13
þ, CD14
þ, CD3
þ, and CD20
þ cells in peripheral blood of M01035, K00339, and K03290 at 3 and 6 mo after
transplantation.
(B) HOXB4GFP or YFP marking levels of FACS-sorted CD13
þ myeloid cells, CD14
þ monocytes, CD3
þ T cells, and CD20
þ B cells from peripheral blood of
M01035 and K00339 at 3 or 6 mo after transplantation as determined by Taqman PCR.
(C) Representative flow-cytometric analysis of marking levels in platelets and red blood cells at 3 mo after transplantation for M01035, K00339, and
K03290.
DOI: 10.1371/journal.pmed.0030173.g005
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Expansion of Primate Repopulating Cellslymphoid expansion, however, was less pronounced com-
pared to reports by Schiedlmeier et al. [24], emphasizing the
importance of HOXB4 expression levels on lymphocyte and
myeloid differentiation. In addition, our Taqman PCR results
suggest that some of the decreased HOXB4GFP expression in
lymphocytes may be due to decreased expression in these
cells rather than to a block in lymphoid differentiation.
Our ﬁndings in the nonhuman primate model differ from
results in the murine models, where HOXB4 overexpression
appears to equally expand short- and long-term repopulating
cells ([21]; unpublished data). This difference may be due to
inherent differences in the biology of stem cells between mice
and nonhuman primates. Another possible explanation is that
HOXB4 expression in mouse cells is higher and potentially
more stable ([24,34]; H.-P. Kiem, unpublished data).
In conclusion, our results demonstrate that HOXB4-
mediated expansion of CD34
þ cells leads to a signiﬁcantly
improved engraftment of short-term repopulation cells with
the potential to prevent severe neutropenia after myeloa-
blative HSC transplantation. Our data also suggest that
HOXB4 may provide a growth advantage to long-term
repopulating cells. Thus, these data support further explora-
tion of the beneﬁts of HOXB4-mediated ex vivo expansion of
stem cells to accelerate engraftment, particularly in the
setting of cord blood transplantation where delayed engraft-
ment is a signiﬁcant concern and is associated with increased
complications after transplantation [2,3].
Supporting Information
Figure S1. Kinetics of Absolute Numbers of HOXB4GFP- or YFP-
Expressing Neutrophils in Three Animals that Received HOXB4GFP-
Transduced and HOXB4GFP-Expanded Cells
These data-points are calculated by multiplying the ANCs per llb y
the percentages of HOXB4GFP- or YFP-expressing neutrophils.
Found at DOI: 10.1371/journal.pmed.0030173.sg001 (118 KB TIF).
Figure S2. Absolute Numbers of HOXB4GFP- or YFP-Expressing
Myeloid and Lymphoid Cells as Detected by FACS for Three Animals
at 3 or 6 mo after Transplantation
HOXB4GFP
þor YFP
þcells in CD13
þmyeloid cells, CD14
þmonocytes,
CD3
þ T cells, and CD20
þ B cells from peripheral blood of M01035,
K00339, and K03290 were determined by FACS. Absolute numbers
per ll of these subsets are calculated by multiplying the white blood
cell count by the percentage of HOXB4GFP- or YFP- expressing cells
within these subpopulations in peripheral blood.
Found at DOI: 10.1371/journal.pmed.0030173.sg002 (140 KB TIF).
Figure S3. Absolute Numbers of HOXB4GFP- or YFP-Expressing
Myeloid and Lymphoid Cells as Detected by Taqman PCR for Two
Animals at 3 or 6 mo after Transplantation
CD13
þ myeloid cells, CD14
þ monocytes, CD3
þ T cells, and CD20
þ B
cells from peripheral blood of M01035 and K00339 were sorted by
FACS. DNA lysates of these samples were subjected to Taqman PCR
analysis for the detection of HOXB4GFP- or YFP-integration events.
Absolute numbers per ll of these subsets are calculated by multiplying
the white blood cell count by the percentage of HOXB4GFP- or YFP-
expressing cells within these subpopulations in peripheral blood.
Found at DOI: 10.1371/journal.pmed.0030173.sg003 (86 KB TIF).
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Expansion of Primate Repopulating CellsPatient Summary
Background. Stem cells of the blood system (also called hematopoietic
stem cells [HSCs]) can make all the different cells found in our blood,
including immune cells that protect us against diseases and platelets
that stop bleeding after an injury. Only a very small number of blood
cells are HSCs. A slightly higher proportion of the cells in the bone
marrow are HSCs, and there is also a relatively high proportion of HSCs in
the blood of the umbilical cord (which connects a baby to the mother
during pregnancy). Doctors use HSCs to treat patients with genetic
disorders of the blood or immune systems as well as those who have
blood cancer (leukemia, lymphoma, or myeloma), because those cancers
are treated with chemotherapy or radiation, which kills most blood cells.
Stem cell transplantation can have serious side effects. These are less
likely when the HSCs are as similar as possible to the patient’s own blood
cells. Finding a ‘‘good match’’ as a source for HSCs and then getting
enough of the cells from that source for transplantation are important
components of good treatment.
Why Was This Study Done? Bone marrow has the highest concen-
tration of HSCs. Until recently, it has been the primary source of HSCs for
transplantation. As scientists are learning more about HSCs, the hope is
that the smaller numbers of HSCs that are found in cord blood or regular
blood can somehow be enriched or expanded, thus providing doctors
with a much larger pool from which to choose well-matched HSCs. This
is a study that tests one possible way of expanding HSCs, by inserting an
active copy of a gene that gets stem cells to divide and make more stem
cells. Insertion of the gene in question, called HOXB4, had shown promise
in mouse experiments. The next step after rodent experiments, and
before introducing an experimental new treatment to a small number of
human patients in a clinical trial, is often to test the treatment in larger
animals which more closely resemble human patients. For HSC trans-
plantation, macaques (a type of monkey) are often used at this stage.
What Did the Researchers Do and Find? They treated a total of six
macaques in the following way: first they collected HSCs (mixed with
some other blood cells) from each of the animals (some from bone
marrow, and some from regular blood). They then divided the cells from
each of the animals in half. Into one half, they introduced the HOXB4
gene, together with a marker that makes the cells fluoresce in green.
They treated the other half exactly the same, except that the only gene
introduced was a marker that makes the cells fluoresce in yellow. They
then grew the cells for a few days in the laboratory to expand them. After
that, the monkeys received high-level radiation that killed off most of
their remaining blood cells (which is similar to the aggressive treatment
of blood cancer in a human patient). After such radiation, the animals die
if they do not get an HSC transplant. The researchers next combined the
two batches of cells from each animal and transplanted them back into
the monkeys. They then followed the monkeys’ recovery and checked
what proportion of the transplanted cells that had moved to and settled
in the bone marrow (i.e., had properly ‘‘engrafted’’) contained the green
or the yellow marker. They found clear differences between the ‘‘green’’
cells and the ‘‘yellow’’ cells. Particularly early after transplantation, there
was a much higher proportion of green cells among the engrafted cells.
What Do These Findings Mean? This suggests that HOXB4 might help
to expand HSCs and speed up the process of engraftment. Given that
patients with rapid engraftment have fewer complications, these results
are encouraging. However, this was a small study, and additional studies
are necessary before the decision can be made as to whether this
treatment appears to be safe and effective and should be tested in
human patients. Regarding future studies, the authors point out that
HOXB4 is available as a recombinant protein (similar to other drugs like
insulin). It may therefore be possible to expand HSCs directly with HOXB4
protein (as opposed to introducing the HOXB4 gene), thus avoiding any
potential side effects from genetic manipulation of the cells.
WhereCanIGetMoreInformationOnline? HereareseveralWebsiteswith
information on HSCs and transplantation of HSCs from different sources.
Fact sheet on bone marrow transplantation from the US National Cancer
Institute:
http://www.cancer.gov/cancertopics/factsheet/Therapy/
bone-marrow-transplant
Pages from the American Cancer Society:
http://www.cancer.org (search within the site for stem cells, cord blood,
and bone marrow transplantation)
Pages from the US National Cord Blood Program:
http://www.nationalcordbloodprogram.org
The US National Marrow Donor Program:
http://www.marrow.org
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